Steven H Collis bought $267K of Bausch + Lomb (BLCO)
Executed Feb 23, disclosed Feb 24, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Feb 24), the stock returned -13.2% (delay-adjusted); from the execution session (Feb 23), -12.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Steven H Collis (Executive Chairman) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Cencora, Inc. (COR). Across 2 priced purchase filings, the average 21-session return was -3.7% from execution and -3.5% from disclosure (delay-adjusted; derived). The largest single filing was $870K of ELV (3,000 sh × $289.84, as filed), executed Mar 5.
Healthcare · Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Ki…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→